- €1.66bn
- €2.23bn
- €684.60m
- 28
- 35
- 48
- 27
Annual cashflow statement for Biotest AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.3 | -30 | -62.7 | -31.7 | 127 |
| Depreciation | |||||
| Non-Cash Items | 1.1 | 25 | 17.5 | 15.7 | -8.9 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -65.1 | -41.3 | 48 | -60.3 | -157 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -33.6 | -16.7 | 33.9 | -40.5 | -2.7 |
| Capital Expenditures | -34.1 | -27 | -18.2 | -29.3 | -33.4 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 26.1 | 12.4 | -5.2 | -7.7 | 34.7 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -8 | -14.6 | -23.4 | -37 | 1.3 |
| Financing Cash Flow Items | 2.7 | 0.1 | 3.6 | -3.8 | 2.1 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 40.5 | 42 | 22.6 | 89.6 | -6.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.1 | 10.5 | 33.1 | 12.1 | -8.1 |